↓ Skip to main content

Dove Medical Press

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia

Overview of attention for article published in OncoTargets and therapy, March 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
2 X users
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
33 Mendeley
Title
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
Published in
OncoTargets and therapy, March 2013
DOI 10.2147/ott.s19901
Pubmed ID
Authors

Gunhild Keller-von Amsberg, Steffen Koschmieder

Abstract

Bosutinib (SKI-606) is an orally available, once-daily, dual Src and Abl kinase inhibitor with promising clinical potential in first-, second-, and third-line treatment of chronic myeloid leukemia (CML). Bosutinib effectively inhibits wild-type BCR-ABL and most imatinib-resistant BCR-ABL mutations except for V299L and T315I. Low hematologic toxicity is a remarkable characteristic of this novel second-generation tyrosine kinase inhibitor, and this has been ascribed to its minimal activity against the platelet-derived growth factor receptor and KIT. Low-grade, typically self-limiting diarrhea, which usually appears within the first few weeks after treatment initiation, represents the predominant toxicity of bosutinib. Other treatment-associated adverse events are mostly mild to moderate. Bosutinib has been approved by the US Food and Drug Administration for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive CML in adult patients with resistance or intolerance to prior therapy. This review summarizes the main properties of bosutinib and the currently available data on its clinical potential in the treatment of CML.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Netherlands 1 3%
Unknown 31 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 24%
Student > Master 8 24%
Student > Ph. D. Student 3 9%
Student > Bachelor 2 6%
Student > Doctoral Student 2 6%
Other 4 12%
Unknown 6 18%
Readers by discipline Count As %
Medicine and Dentistry 12 36%
Chemistry 5 15%
Biochemistry, Genetics and Molecular Biology 4 12%
Agricultural and Biological Sciences 4 12%
Nursing and Health Professions 1 3%
Other 0 0%
Unknown 7 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2014.
All research outputs
#7,356,343
of 25,374,647 outputs
Outputs from OncoTargets and therapy
#378
of 3,016 outputs
Outputs of similar age
#58,472
of 206,322 outputs
Outputs of similar age from OncoTargets and therapy
#7
of 32 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,322 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.